SCHEMBL5544898

SCHEMBL5544898

[c]1ccc(N2CCC(Oc3ccccc3)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 5/20 0.53
NAMPT P43490 1/20 0.51
HRH1 P35367 1/20 0.47
CARM1 Q86X55 1/20 0.47
PRMT6 Q96LA8 1/20 0.47
HRH3 Q9Y5N1 2/20 0.46
DRD2 P14416 3/20 0.43
DRD4 P21917 3/20 0.43
DRD3 P35462 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
SLC6A2 P23975 1/20 0.42
SLC6A3 Q01959 1/20 0.42
OXTR P30559 1/20 0.42
AVPR1A P37288 1/20 0.42
NR3C1 P04150 1/20 0.41
ACACB O00763 1/20 0.41
CHRM4 P08173 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542554 0.84 SMN1; SMN2 (0.51) HRH3DRD2SMN1; SMN2ACACB
SCHEMBL2091594 0.84 HRH3 (0.41) FFAR4NAMPTHRH3SMN1; SMN2ACACB
SCHEMBL2092037 0.84 ACACB (0.46) FFAR4HRH1HRH3SLC6A2SLC6A3
SCHEMBL3708111 0.83 FFAR4 (0.56) FFAR4NAMPTHRH1CARM1PRMT6
SCHEMBL2090413 0.83 FFAR4 (0.47) FFAR4NAMPTHRH1CARM1PRMT6
SCHEMBL6933621 0.83 FFAR4 (0.47) FFAR4NAMPTHRH1CARM1PRMT6
SCHEMBL2095970 0.80 KCNH2 (0.51) FFAR4SLC6A2ACACBCHRM4
SCHEMBL2096729 0.80 TEAD1 (0.45)
SCHEMBL13406711 0.80 HRH3 (0.52) FFAR4NAMPTHRH1CARM1PRMT6
SCHEMBL5536098 0.80 CTSV (0.49) FFAR4NAMPTDRD2DRD4ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 FFAR4 338/4885NAMPT 1094/4885HRH1 668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.